Imkeldi, imatinib oral solution
Philadelphia-chromosome-positive CML in chronic phase (adults and pediatrics) and Ph+ ALL (pediatrics, in combination… · Hematology/oncology (Ph+ CML and Ph+ ALL)
About Imkeldi
Imkeldi (imatinib oral solution) is manufactured by Shorla Oncology and indicated for CML/GIST. It is an Oral liquid BCR-ABL tyrosine kinase inhibitor (80 mg/mL strawberry-flavored solution) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Imkeldi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Imkeldi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Imkeldi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Imkeldi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Imkeldi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.